NCNuno Cardim

Nuno Cardim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nuno Cardim has a total of 246 co-authors. Here are the top co-authors by number of shared publications:

  • Dulce Brito

    Cardiology Department, Unidade Local de Saúde Santa Maria - Santa Maria Hospital Av. Prof. Egas Moniz, 1649-028, Lisboa, Portugal; Centro Académico de Medicina de Lisboa (CAML), Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028, Lisboa, Portugal; Heart Failure and Cardiomyopathies Research Unit, CCUL@RISE, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028, Lisboa, Portugal

    4 shared publications
  • Adriana Belo

    Centro Nacional de Coleção de Dados em Cardiologia (CNCDC), Sociedade Portuguesa de Cardiologia, Portugal

    3 shared publications
  • António Freitas

    Hospital Fernando da Fonseca, Amadora-Sintra, Portugal

    3 shared publications
  • Bogdan Alexandru Popescu

    University of Medicine and Pharmacy 'Carol Davila' - Euroecolab, Emergency Institute for Cardiovascular Diseases 'Prof. Dr. C. C. Iliescu' , Bucharest

    3 shared publications
  • Daniel Ferreira

    Cardiovascular Centre, Hospital da Luz Lisboa, Lisbon, Portugal

    3 shared publications
  • Jorge Mimoso

    Serviço de Cardiologia do CHU Algarve, Faro, Portugal

    3 shared publications

Latest Publications

  • Multimodality Imaging for Left Atrial Appendage Closure: Practical Guidance Across Preprocedural, Intraprocedural, and Postprocedural Phases

    by Issam Motairek, Bryan Abadie, Paul C. Cremer, Mohamed Kanj, Serge Harb, Rogerio Teixeira, Stefano Nistri, Marta Sitges, Tyler Taigen, Heidi Ferrini, et al.

    Left atrial appendage closure is an increasingly used stroke prevention therapy for patients with atrial fibrillation who are unable to maintain long-term anticoagulation. Imaging quality and consistency are central to procedural safety and long-term outcomes, yet practice varies widely across centers. This review presents a practical, phase-based multimodality imaging framework intended to provide guidance and minimum standards for image acquisition and interpretation across all phases of left atrial appendage closure care, including preprocedural planning and thrombus exclusion, intraprocedural guidance and complication detection, and postprocedural surveillance for device-related thrombus and peridevice leak. Because sizing rules, sealing mechanisms, and leak patterns differ between the 2 contemporary platforms, device-specific considerations for the Watchman and Amulet systems are addressed throughout. Transesophageal echocardiography remains the reference standard for thrombus detection and procedural guidance, while cardiac computed tomography offers high spatial resolution, detailed 3-dimensional characterization, and complementary leak assessment, with optimal modality selection influenced by patient characteristics, operator expertise, and institutional resources. Intracardiac echocardiography and mini transesophageal echocardiographic support anesthesia-sparing workflows. Standardized device-related thrombus and peridevice leak classification and harmonized imaging protocols can enhance reproducibility and facilitate cross-center comparisons. Emerging technologies including computed tomography first workflows, 4-dimensional imaging, AI applications, and computational modeling further advance precision planning and surveillance.

  • Role of multi-modality cardiac imaging in the management of patients with hypertrophic cardiomyopathy in 2025. A Clinical Consensus Statement of the European Association of Cardiovascular Imaging (EACVI) of the ESC

    by Nuno Cardim, Kristina Haugaa, Saidi A Mohiddin, Rocio Hinojar, Alexander Hirsch, Liliana Szabo, Tomaz Podlesnikar, Erica Dall’ARmellina, Matteo Cameli, Giulia Elena Mandoli, et al.

    After the 2014, European Society of Cardiology (ESC) guidelines on hypertrophic cardiomyopathy (HCM) were published, the European Association of Cardiovascular Imaging (EACVI) of the ESC developed the 2015 EACVI consensus paper on multi-modality imaging (MMI) in HCM, providing in-depth knowledge on the role of imaging in this disease. Since then, new evidence on HCM diagnosis, management and patient prognosis has accumulated, and the role of MMI has further expanded. Now that the 2023 ESC guidelines on cardiomyopathies have been published, a new EACVI document on MMI in HCM is needed, providing state-of-the-art, in-depth knowledge of imaging in HCM. The scope of this document is to focus on the role of the different imaging techniques in HCM in a logical, didactic and comprehensive way using a multi-modality approach. We provide our vision for future directions on MMI in HCM.


  • Open Access

    Treatment Response to Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy: 96-Week Results From the EXPLORER Cohort of the MAVA–Long-Term Extension Cardiac Magnetic Resonance Imaging Substudy

    by Sara Saberi, Christopher M. Kramer, Artur OręZiak, Ahmad Masri, Roberto Barriales-Villa, Theodore P. Abraham, Neal K. Lakdawala, Andrew Wang, Lubna Choudhury, Florian Rader, et al.


  • Open Access

    The Complex Puzzle of Hypertrophic Phenotype: A Practical Approach for the Clinician

    by Alex dos Santos Felix, Silvio Henrique Barberato, Marcelo Dantas Tavares de Melo, Sílvia Aguiar Rosa, Nuno Cardim

    Left ventricular hypertrophy (LVH) represents a frequent observation in clinical practice. Nonetheless, the hypertrophic phenotype emerges as a common manifestation of diverse conditions, thereby presenting a diagnostic conundrum for clinicians. Differentiation among the etiologies of LVH is imperative for therapy decision-making, as different approaches must be implemented for distinct conditions, such as LVH secondary to loading changes, hypertrophic cardiomyopathy (HCM), or HCM mimics. In some instances, an erroneous or late diagnosis may lead to a progression of the underlying disease with worsening functional capacity, high morbidity and mortality. The rational use of cardiovascular multimodality imaging is of great importance when carried out in addition to a thorough clinical assessment and correlated with electrocardiographic findings, providing clues to fill the gaps, being, most of the time, the missing piece to solve this challenging puzzle. An integrative approach is of paramount importance for the evaluation of these patients, as they are often followed by several specialties, with varied systemic manifestations. Although a multidisciplinary team is needed for an optimized follow-up of these patients, the most important player in this journey is the clinician, whose mission is to bring together all the red flags and coordinate all the data for an assertive diagnosis. The objective of this review is to provide a pragmatic methodology, highlighting important clues for discriminating among the diverse conditions that result in LVH.

  • Open Access

    O Complexo Quebra-Cabeça do Fenótipo Hipertrófico: Uma Abordagem Prática para o Clínico

    by Alex dos Santos Felix, Silvio Henrique Barberato, Marcelo Dantas Tavares de Melo, Sílvia Aguiar Rosa, Nuno Cardim

    Resumo A hipertrofia ventricular esquerda (HVE) é frequentemente observada na prática clínica. No entanto, o fenótipo hipertrófico é uma manifestação comum de diversas condições, representando, portanto, um enigma para os médicos em termos de diagnóstico. Diferenciar as etiologias da HVE é fundamental para a tomada de decisão terapêutica, pois diferentes abordagens devem ser implementadas para condições distintas, como HVE secundária a alterações de carga, cardiomiopatia hipertrófica (CMH) ou mimetizadores de CMH. Em alguns casos, um diagnóstico incorreto ou tardio pode levar à progressão da doença de base com perda adicional da capacidade funcional, alta morbidade e mortalidade. O uso racional da multimodalidade de imagem cardiovascular é de extrema importância quando são realizados em conjunto com uma avaliação clínica completa e correlacionados com os achados eletrocardiográficos, fornecendo pistas para preencher lacunas. Na maioria das vezes, os exames de imagem são a peça que falta para resolver esse quebra-cabeça desafiador. Uma abordagem integral é de suma importância na avaliação desses pacientes, pois, muitas vezes, são acompanhados por diversas especialidades, com manifestações sistêmicas variadas. Embora seja necessária uma equipe multidisciplinar para um acompanhamento otimizado desses pacientes, o agente mais importante nessa jornada é o clínico, cuja missão é reunir todos os sinais de alerta e coordenar todos os dados para um diagnóstico assertivo. O objetivo desta revisão é fornecer uma metodologia pragmática, destacando pistas importantes para discriminar as diversas condições que resultam em HVE.


  • Open Access

    Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA‐HCM

    by Caroline J Coats, Ahmad Masri, Michael E Nassif, Roberto Barriales-Villa, Michael Arad, Nuno Cardim, Lubna Choudhury, Brian Claggett, Hans-Dirk Düngen, Pablo Garcia-Pavia, et al.

    Background: Aficamten, a novel cardiac myosin inhibitor, reversibly reduces cardiac hypercontractility in obstructive hypertrophic cardiomyopathy. We present a prespecified analysis of the pharmacokinetics, pharmacodynamics, and safety of aficamten in SEQUOIA‐HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM). Methods and Results: A total of 282 patients with obstructive hypertrophic cardiomyopathy were randomized 1:1 to daily aficamten (5–20 mg) or placebo between February 1, 2022, and May 15, 2023. Aficamten dosing targeted the lowest effective dose for achieving site‐interpreted Valsalva left ventricular outflow tract gradient <30 mm Hg with left ventricular ejection fraction (LVEF) ≥50%. End points were evaluated during titration (day 1 to week 8), maintenance (weeks 8–24), and washout (weeks 24–28), and included major adverse cardiac events, new‐onset atrial fibrillation, implantable cardioverter‐defibrillator discharges, LVEF <50%, and treatment‐emergent adverse events. At week 8, 3.6%, 12.9%, 35%, and 48.6% of patients achieved 5‐, 10‐, 15‐, and 20‐mg doses, respectively. Baseline characteristics were similar across groups. Aficamten concentration increased by dose and remained stable during maintenance. During the treatment period, LVEF decreased by −0.9% (95% CI, −1.3 to −0.6) per 100 ng/mL aficamten exposure. Seven (4.9%) patients taking aficamten underwent per‐protocol dose reduction for site‐interpreted LVEF <50%. There were no treatment interruptions or heart failure worsening for LVEF <50%. No major adverse cardiovascular events were associated with aficamten, and treatment‐emergent adverse events were similar between treatment groups, including atrial fibrillation. Conclusions: A site‐based dosing algorithm targeting the lowest effective aficamten dose reduced left ventricular outflow tract gradient with a favorable safety profile throughout SEQUOIA‐HCM. Registration: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT05186818.


  • Open Access

    Por uma “Gazeta Médica” cada vez melhor

    by Helena Donato, Nuno Cardim, João Subtil